Anne Hamilton

Anne Hamilton

Auto-generated profile, based on publicly available information

Anne Hamilton

Peter MacCallum Cancer Centre, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
NBNikki L. Burdett
Nikki L. Burdett
MWMadelynne O. Willis
Madelynne O. Willis
KAKathryn Alsop
Kathryn Alsop
AHAllison L. Hunt
Allison L. Hunt
APAhwan Pandey
Ahwan Pandey
ECElizabeth L Christie
Elizabeth L Christie

17 January 2019 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CLChee Khoon Lee
Chee Khoon Lee
CSClare L Scott
Clare L Scott
GLGeoffrey J. Lindeman
Geoffrey J. Lindeman
AHAnne Hamilton
Anne Hamilton
ELElizabeth Lieschke
Elizabeth Lieschke
MFMichael Friedlander
Michael Friedlander
We conducted a Phase 1 study to evaluate safety and activity of olaparib tablets and oral cyclophosphamide. Patients had metastatic breast cancer (BC) or recurrent high-grade serous ovarian cancer (HGSOC), performance status 0–2, and ≤3 lines of prior therapy. Patients were treated using a dose escalation strategy with cohort expansion once maximal tolerated dose (MTD) was determined. Dose level 1 (DL1): olaparib 300 mg bid, cyclophosphamide 50 mg on days 1, 3, and 5, weekly. DL2: olaparib 300 mg bid, cyclophosphamide 50 mg, days 1–5 weekly. Of 32 patients, 23 had HGSOC (germline BRCA mutation [gBRCAm] 70%) and 9 had BC (gBRCAm 67%). Four were treated at DL1 and 28 at DL2, the MTD. Haematological adverse events (AEs) were most common: grade 3/4 AEs: lymphopenia 75%, anaemia 31%, neutropenia 37%, thrombocytopenia 47%. Two permanently discontinued treatment due to haematological AEs. In BC, no objective response was reported. Unconfirmed objective response was 48% and 64% for all HGSOC and gBRCAm subset, respectively. CA125 responses were 70% (all HGSOC) and 92% (gBRCAm). In HGSOC and BC, olaparib 300 mg bid and cyclophosphamide 50 mg on days 1–5 weekly were tolerable and active, particularly in gBRCAm, and is worthy of further investigation.

1 November 2020 in JCO Precision Oncology
Verified
Journal Article
Closed access
CCCiara Conduit
Ciara Conduit
SLStephen Luen
Stephen Luen
HXHuiling Xu
Huiling Xu
DBDavid Byrne
David Byrne
SFStephen Fox
Stephen Fox
AHAnne Hamilton
Anne Hamilton

26 January 2021 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SSSunit Sarkar
Sunit Sarkar
BTBen Tran
Ben Tran
LHLisa G. Horvath
Lisa G. Horvath
MLMichael Lam
Michael Lam
PSPeter Savas
Peter Savas
AHAnne Hamilton
Anne Hamilton